- Auteur(s) : Ali Hasbini, Fabienne Ozanne, Hanifa Ammarguellat, Jacky Crequit, Thierry Dolige, Eric Bouchaert, Jean-Luc Dutel, Catherine Durdux
, Service de radiothérapie-oncologie, Centre hospitalier, avenue Léon-Blum, 60021 Beauvais Cedex.
- Mots-clés : radiotherapy, chemotherapy, association, non small cell lung carcinoma.
- Page(s) : 599-611
- Année de parution : 2002
Optimal treatment of non operable localized non small cell lung carcinoma (NSCLC) continues to evolve. Increasing overall survival must evolute through improving local tumoral control and eradication of probable occulte metastasis. Historically, median survival varies between 7 and 10 months with a standard conventionnal fractionnated radiotherapy (RT). Induction chemotherapy (CT) followed by RT has demonstrated its superiority over RT alone, modality which is widely utilised. Other studies revealed best results with decreasing metastatic relapses. Three independent meta-analysis confirmed benefit obtained with cisplatin based CT followed by RT that allowed to consider this association as a gold standard. Other authors demonstrated an improvement of local control and survival with concomitant RT-CT or hyperfractionnated accelerated RT. Results of all of these new therapeutic modalities still poor. Implication of new CT drugs has conducted for an emergence of new studies finding to demonstrate more encouraging results. Randomized trials are conducted in this way.